Skip to main content
Equibles
CPMD logo

CPMD · Cannapharmarx, Inc. · Metrics

Track CPMD — free

Use CPMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CPMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 18, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on current financial projections, the Company does not have sufficient existing cash resources to fund its current operations. Accordingly, there is substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 18, 2026
Customer concentration — top customer 63% of revenue

One customer — 63% of revenue (the year ended December 31, 2025)

“During the year ended December 31, 2025, the Company also recognized revenue of $861,476 (2024 - $nil) from the sale of cannabis products to a pharmaceutical company based in Germany. This comprised 63% of the revenues generated during the year ended December 31, 2025.”

One customer — 29% of revenue (the year ended December 31, 2025)

“During the year ended December 31, 2025, the Company recognized revenue of $394,633 (2024 - $770,265) from Cantek (Note 12), which was 29% of the total revenue (2024 - 94%).”
View the 10-K filed Mar 31, 2026
Market Cap
$1.42M
Shares
708.69M
Volume · Oct 20 5900 Avg daily vol (3M) 67.59K

CPMD metrics

52 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$1.42M

Price action

20 metrics
Price change (1W)
+0.0%
Price change (30D)
+0.0%
Price change (3M)
-4.8%
Price change (6M)
-48.7%
Price change (YTD)
-61.5%
Price change (1Y)
-58.3%
Trailing year
Price change (5Y)
-93.3%
52-week high
$0.01
52-week low
$0.00
Change from 52-week high
-77.3%
Change from 52-week low
+185.7%
Annualized volatility
407.8%
Annualized volatility (3M)
—
Beta
2.5
RSI (14D)
45.3
Price vs SMA 50
-2.3%
Price vs SMA 200
-43.9%
Avg volume (3M)
67,586
Relative volume
0.1
Average dollar volume
$139

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
708.69M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.8×
reciprocal yield 119.9%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-798.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
-88.8%
Operating margin
-170.1%
Trailing 12 months
Net margin
-666.2%
Gross profit (TTM)
−$1.51M
Operating profit (TTM)
−$2.89M
Net income (TTM)
−$11.32M
Trailing 12 months
Diluted EPS (TTM)
$-0.02
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.05

Growth

11 metrics
Revenue growth YoY
+19.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.70M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-164.2%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
−$4.07M
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
-1.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$555
Total assets
$6.89M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$112,283
Capital expenditures (TTM)
$60,637
R&D (TTM)
$620,211
SG&A (TTM)
—
Stock compensation (TTM)
$180,979
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1081938 Visit website Investor relations